Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell long cancer

Purpose: This multicenter phase II trial wets performed to determine tumor efficacy and tolerance of the oral platinum drug JM216 in patients with sma ll-cell lung cancer (SCLC). Patients and Methods: patients with SCLC limited disease unfit for intensiv e chemotherapy or those with extensive disease received JM216 120 mg/m(2)/d for 5 consecutive days every 3 weeks, Individual dose escalation to 140 mg /m(2)/d was allowed if toxicity was less than or equal to grade 2 according to the National Cancer Institute Common Toxicity Criteria, tumor response was evaluated according to World Health Organization criteria, Results: Twenty-seven patients were assessable for toxicity and 26 for tumo r response, Eighty-eight cycles were administered. Common Toxicity Criteria grade 3 and 4 hematologic toxicities were neutropenia in 15.9% and 3.7%, l ymphocytopenia in 47.6% and 17.1%, and thrombocytopenia in 19.5% and 10.3% of cycles, respectively. One patient suffered from neutropenic fever Nausea , vomiting, and diarrhea were the most common nonhematologic toxicities. Ex cept For grade 4 diarrhea in one patient, no grade 4 nonhematologic toxicit y was observed, No severe neurotoxicity or nephrotoxicity was observed, Tum or response rate was 10 of 26 (38%; 95% confidence interval, 19% to 58%), e xcluding five unconfirmed partial responses. No complete responses were obs erved. Median overall time to progression was 110 days (range, 5 to 624 day s), Median overall survival time was 210 days (range, 5 to 624 days), Conclusion: Oral JM216 is active in previously untreated patients with SCLC and shows mild toxicities, J Clin Oncol 17:3822-3827, (C) 1999 by American Society of Clinical Oncology.